Aug. 27, 2007 -
Pfizer Inc. (NYSE: PFE) and
Bristol-Myers Squibb Company (NYSE: BMY) ("companies") have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT- 1 discovery program includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes...
Pfizer's Press Release. -
BMS' Press Release. -
(The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals Corporation in June 2006, including a pre-clinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer.) 14 June 2006 Bayer Pharma's Press Release.
Aug. 27, 2007 - Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Company (NYSE: BMY) ("companies") have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT- 1 discovery program includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes... Pfizer's Press Release. - BMS' Press Release. -
(The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals Corporation in June 2006, including a pre-clinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer.) 14 June 2006 Bayer Pharma's Press Release.
